Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
– Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments –CAMBRIDGE, Mass. […]
DPW Holdings Announces That Construction Has Resumed on Luxury Hotel in Tribeca
Newport Beach, Cal., June 12, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” […]
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable […]
Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced […]
Hooker Furniture Reports Preliminary Results for First Quarter During February-April COVID Crisis
MARTINSVILLE, Va., June 12, 2020 (GLOBE NEWSWIRE) — Hooker Furniture Corporation (NASDAQ-GS: HOFT) today reported its preliminary financial results for […]
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients12.1 months median OS in intention-to-treat MDS […]
Qingke Announces New Chief Operating Officer
SHANGHAI, China, June 12, 2020 (GLOBE NEWSWIRE) — Q&K International Group Limited (NASDAQ: QK) (“Qingke” or the “Company”), a leading […]
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
-Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for […]
X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020
Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, […]
BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology […]
